Genetics Core

$176,850P01FY2013HDNIH

Hugo W. Moser Res Inst Kennedy Krieger, Baltimore MD

Investigators

Linked publications & trials

Paper 38696263 Paper 38476636 Paper 37899501 Paper 37438872 Paper 34873819 Paper 33337378 Paper 32435687 Paper 32057305 Paper 30555031 Paper 28843780 Paper 28554490 Paper 28452584 Paper 27911079 Paper 26607552 Paper 26593971 Paper 26166206 Paper 24732579 Paper 24515445 Paper 24273589 Paper 23949829 Paper 23949827 Paper 23937371 Paper 23784802 Paper 23635391 Paper 23096997 Paper 22592955 Paper 22474448 Paper 22465657 Paper 22156442 Paper 22057025 Paper 21124956 Paper 21041786 Paper 20597723 Paper 20535591 Paper 20401180 Paper 19633729 Paper 19513990 Paper 18702557 Paper 18696092 Paper 18635289 Paper 18578579 Paper 18571319 Paper 18464295 Paper 18408366 Paper 18240877 Paper 18240873 Paper 17910085 Paper 17826910 Paper 17620492 Paper 17353095 Paper 17334655 Paper 17237937 Paper 16926067 Paper 16539728 Paper 16316425 Paper 16212450 Paper 16122874 Paper 16046031 Paper 15525565 Paper 15471513 Paper 15126119 Paper 15000676 Paper 15000666 Paper 14994244 Paper 14749133 Paper 14723654 Paper 14529278 Paper 14520653 Paper 12901708 Paper 12780334 Paper 12354318 Paper 11983636 Paper 11966329 Paper 11904752 Paper 11896805 Paper 11515787 Paper 11257432 Paper 11115020

Abstract

This Core has been an integral part of the Program Project since its inception. It will continue to provide investigators with cytogenetic documentation of DS whenever this information is not available in the medical records of the participant. In addition, it will continue to provide Apolipoprotein E (APOE) genotyping and will maintain archives of DNA as well as frozen buffy coat cells and immortalized lymphoblastoid cell lines. Together with the detailed characterization of these people provided by other Program components, these resources will be of great value for our current and future investigations as new biomarkers are identified as possible diagnostic indicators or risk factors. For example, when feasible, some of the buffy coat samples have been provided to determine whether telomere shortening may serve as a biomarker of mild cognitive impairment/dementia status in DS.

View original record on NIH RePORTER →